Media Centre
Latest press releases
-
Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
-
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer
-
Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
